Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1398
Shown on this page
12
Current sort
Recently updated
Campus scope
UCSF, San Francisco, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCSF, San Francisco, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1297–1308 of 1,398 matching trials with a site at UCSF, San Francisco, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional Results available

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

NCT03057054
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Leukemia, Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Lactobacillus plantarum strain 299, Lactobacillus plantarum strain 299v, Placebo Administration
Procedure · Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 25 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Nov 7, 2026, 1:32 PM EST
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Nov 7, 2026, 1:32 PM EST
Recruiting No phase listed Observational

Stroke Recovery Initiative - Registry for Stroke Research Studies

NCT03318432
Status at this site: Recruiting
View directory record Official record
Conditions
Stroke, Acute Stroke, Ischemic Stroke, Hemorrhagic Stroke, Subarachnoid Hemorrhage, Cerebral Ischemia, Cerebral Infarction, Cerebral Stroke, Cerebral Vascular Accident
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Nov 7, 2026, 1:32 PM EST
Recruiting No phase listed Observational

A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

NCT06504589
Status at this site: Recruiting
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Nov 7, 2026, 1:32 PM EST
Recruiting Phase 3 Interventional

Pediatric Dose Optimization for Seizures in Emergency Medical Services

NCT05121324
Status at this site: Recruiting
View directory record Official record
Conditions
Seizures
Interventions
Standardized seizure protocol, Conventional seizure protocol
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 13 Years
Enrollment
6,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Nov 7, 2026, 1:32 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults

NCT07171164
Status at this site: Recruiting
View directory record Official record
Conditions
Older Adults Without Any Specific Clinical Condition, Social Networks, RSV Immunization, Vaccine Uptake
Interventions
Motivate Aim: CHW text message reminders and counseling, Motivate Aim: CHW text message reminders only, Activate Aim: CHW text message reminders and counseling, Activate Aim: CHW text message reminders only
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Nov 7, 2026, 1:32 PM EST
Active, not recruiting Phase 3 Interventional

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577
Site status not listed — check the official record
View directory record Official record
Conditions
Melanoma
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,089 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
34
States / cities
Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Nov 7, 2026, 1:32 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

NCT05972629
Site status not listed — check the official record
View directory record Official record
Conditions
Phenylketonuria
Interventions
SAR444836
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Nov 7, 2026, 1:32 PM EST
Recruiting Not applicable Interventional

Model-based Electrical Brain Stimulation

NCT05327387
Status at this site: Recruiting
View directory record Official record
Conditions
Medication Refractory Epilepsy Patients With Electrodes Already Implanted Based on Clinical Criteria for Standard Monitoring
Interventions
model-based electrical brain stimulation
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Nov 7, 2026, 1:32 PM EST
Active, not recruiting Phase 1 Interventional

GDNF Gene Therapy for Parkinson's Disease

NCT04167540
Site status not listed — check the official record
View directory record Official record
Conditions
Parkinson's Disease
Interventions
AAV2-GDNF
Biological
Lead sponsor
Brain Neurotherapy Bio, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Irvine, California • San Francisco, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Nov 7, 2026, 1:32 PM EST
Active, not recruiting Phase 4 Interventional

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

NCT06074510
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer
Interventions
Piflufolastat F 18 Intravenous Solution [PYLARIFY]
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older · Male only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Nov 7, 2026, 1:32 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

NCT05845814
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Urothelial Neoplasms
Interventions
Coformulated favezelimab/pembrolizumab, Coformulated vibostolimab/pembrolizumab, EV, Pembrolizumab
Biological · Combination Product
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
La Jolla, California • Orange, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Nov 7, 2026, 1:32 PM EST

About this UCSF institution page

What this page lists
ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of California, San Francisco at any site, browse by condition, or browse by U.S. city.